viewCellmid Limited

Cellmid gaining ground in USA and China following advances in Japan and Australia

Cellmid Limited (ASX:CDY) CEO Maria Halasz provides a show and tell updating Proactive Investors on progress and strategies for the company’s international portfolio of products, including the world’s first non-injectable filler product.

Speaking on growth drivers, Halasz says, "as far as our consumer health business is concerned; we definitely have new product ranges, we've got our e-commerce platform and new distribution channels in new geographic regions that will drive sales and growth. As far as our biotech portfolio is concerned... we are meeting our intellectual leaders, but the actual patents are owned by the company... it's cost effective but more importantly it really is wide spread development of a really large portfolio of patents."

Quick facts: Cellmid Limited

Price: 0.195 AUD

Market: ASX
Market Cap: $18.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid makes key retail collaborations and continues to kick strategic goals

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive on a number of recent key announcements, including a new collaboration with a major retail chain in Europe, a new agreement to sell Evolis in 400 Priceline pharmacies and signing up with the...

on 21/11/19

2 min read